Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(66.7%)
Phase 3
1(33.3%)
3Total
Phase 4(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07338851Not Yet Recruiting

the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines

Role: collaborator

NCT05204589Phase 3Completed

Heterologous Boost Immunization with an Aerosolised Ad5-nCoV After Two-dose Priming with an Inactivated SARS-CoV-2 Vaccine

Role: collaborator

NCT04054882Phase 4Completed

Evaluation of the Safety and Immunogenicity of Simultaneously Administration of sIPV and DTaP

Role: collaborator

NCT04638985Phase 4Unknown

Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMR

Role: collaborator

All 4 trials loaded